{"id":21459,"date":"2023-03-03T23:28:00","date_gmt":"2023-03-03T15:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21459"},"modified":"2025-01-13T23:32:42","modified_gmt":"2025-01-13T15:32:42","slug":"echo-biotech-secures-series-a-funding-for-exosomes-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21459","title":{"rendered":"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development"},"content":{"rendered":"\n

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised \u201ctens of millions\u201d of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech’s engineering exosomes technology platform and the expansion of its solution offerings.<\/p>\n\n\n\n

Company Background and Services<\/strong>
Echo Biotech, in partnership with over 100 key hospitals in China, provides a range of services related to exosomes. These include Contract Manufacturing (CMC), Contract Research (CRO), and Contract Development and Manufacturing Organization (CDMO) services. The company’s offerings are based on its exomics platform, which provides high-throughput multi-omics solutions. Additionally, Echo Biotech focuses on basic research solutions through its engineering exocrine transformation platform, ModiExo, and the research and development of exocrine innovative drugs using its engineering exocrine platform, Echome.<\/p>\n\n\n\n

Future Prospects<\/strong>
The Series A++ financing round is a significant step for Echo Biotech, providing the necessary capital to advance its exosomes technology platform. By iterating its technology and expanding its solutions, Echo Biotech aims to enhance its capabilities in the exosomes drug development space. This strategic move positions the company to better serve its partners and contribute to the advancement of exosomes-based therapies, potentially improving patient outcomes in various medical conditions.<\/a>-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised \u201ctens of millions\u201d of renminbi…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,3142],"class_list":["post-21459","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-echo-biotech"],"yoast_head":"\nEcho Biotech Secures Series A++ Funding for Exosomes Drug Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised \u201ctens of millions\u201d of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech's engineering exosomes technology platform and the expansion of its solution offerings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21459\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21459\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-03T15:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T15:32:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21459#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21459\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development\",\"datePublished\":\"2023-03-03T15:28:00+00:00\",\"dateModified\":\"2025-01-13T15:32:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21459\"},\"wordCount\":231,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Echo Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21459#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21459\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21459\",\"name\":\"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-03T15:28:00+00:00\",\"dateModified\":\"2025-01-13T15:32:42+00:00\",\"description\":\"Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised \u201ctens of millions\u201d of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech's engineering exosomes technology platform and the expansion of its solution offerings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21459#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21459\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21459#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development - Insight, China's Pharmaceutical Industry","description":"Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised \u201ctens of millions\u201d of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech's engineering exosomes technology platform and the expansion of its solution offerings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21459","og_locale":"en_US","og_type":"article","og_title":"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21459","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-03T15:28:00+00:00","article_modified_time":"2025-01-13T15:32:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21459#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21459"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development","datePublished":"2023-03-03T15:28:00+00:00","dateModified":"2025-01-13T15:32:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21459"},"wordCount":231,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Echo Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21459#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21459","url":"https:\/\/flcube.com\/?p=21459","name":"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-03T15:28:00+00:00","dateModified":"2025-01-13T15:32:42+00:00","description":"Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised \u201ctens of millions\u201d of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech's engineering exosomes technology platform and the expansion of its solution offerings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21459#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21459"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21459#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Echo Biotech Secures Series A++ Funding for Exosomes Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21459"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21459\/revisions"}],"predecessor-version":[{"id":21461,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21459\/revisions\/21461"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}